Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...

编者按：2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会（ASCO-GU）盛大召开，前列腺癌领域迎来术语体系革新、多项重磅研究数据更新与治疗格局的迭代升级。会议期间，肿瘤瞭望-泌尿时讯特邀美国威尔康奈尔医学院Scott T. Tagawa教授，围绕本届大会前列腺癌领域进展及精准治疗的未来方向，展开深度解读。 01 2026年ASCO GU研讨会汇聚了全球专家，共同分享泌尿生殖系统肿瘤领域的突破性研 ...

Similar 3-year metastasis-free survival, fewer hot flashes, more gynecomastia ...

On track to share data from first two dose levels in 2H 2026Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative ...

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver ...

Patches that lower testosterone by delivering oestradiol, a form of oestrogen, through the skin were just as effective as ...

Patients with a type of prostate cancer known as metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted ...

Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a side effect so debilitating that patients often refuse the life-saving ...

Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone. This is an ASCO Meeting Abstract from the ...

Watchdog finds failings in prostate cancer treatment in North Wales going back almost a decade.